Press Releases

R&D Discussion in New York City to Review IL-12’s Potential to Treat Ovarian Cancer Program Features Ovarian Cancer Thought Leaders, OVATION 2 Study Investigators, and Oncology Experts LAWRENCEVILLE, N.J. , Aug. 28, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc.

Conference Call Begins Today at 11:00 a.m. Eastern Time LAWRENCEVILLE, N.J. , Aug. 14, 2024 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN) , a clinical-stage company in late-stage development with its DNA-mediated immuno-oncology therapy, today reported financial results for the three and six

LAWRENCEVILLE, N.J. , Aug. 07, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc . (NASDAQ: IMNN) , a clinical-stage drug-development company focused on developing DNA-mediated immunotherapy and next-generation vaccines, announces that the Company will host a conference call at 11:00 a.m.

LAWRENCEVILLE, N.J. , July 31, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN ), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, today announced that it has entered into definitive securities purchase agreements for a registered direct offering of its

Phase 2 OVATION 2 Study of IMNN-001 a dministered with standard-of-care chemotherapy as first-line treatment demonstrates a hazard ratio of 0.74 in overall survival (OS) in the intent-to-treat patient population compared with the standard-of-care control arm OS was extended by 15.7 months in

Results to be announced at 8:00 a.m. Eastern time , conference call to begin at 8:30 a.m. Eastern time LAWRENCEVILLE, N.J. , July 29, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN ), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, will issue a news

Novel IL-12 Immunotherapy Administered with Standard of Care as First-Line Treatment Expects topline results by the end of July LAWRENCEVILLE, N.J. , June 24, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN ), a clinical-stage company in advanced development of its non-viral DNA-mediated

DNA vaccine proof-of-concept study expected to demonstrate an “mRNA better” platform LAWRENCEVILLE, N.J. , June 05, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN ), a clinical-stage company focused on developing non-viral DNA-mediated immunotherapy and evaluating an adaptation of the

LAWRENCEVILLE, N.J. , May 15, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc.  (NASDAQ: IMNN) , a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, announces that an abstract describing a Phase 2 study with IMNN-001 plus

Proof-of-concept study for Imunon’s first vaccine utilizing its proprietary PlaCCine platform is now open for enrollment Topline results expected this year LAWRENCEVILLE, N.J. , May 13, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN ), a clinical-stage drug development company focused on